Table 2.
Stakeholder perspectives on available medications and the role of research.
| Disagreed/Strongly Disagreed | Agree/Strongly Agree | Neutral/Unsure | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Neonatologists n = 37, Nurses n = 135, Parents n = 54 unless otherwise indicated by reference to the table footnote. | Neo-natologists (%) | Nurses (%) | Parents (%) | Neo-natologists (%) | Nurses (%) | Parents (%) | Neo-natologists (%) | Nurses (%) | Parents (%) |
| Stakeholder Perspectives on Available Medications and the Role of Research | |||||||||
| Current medications are sufficient | 82 | 36 | 31 | 5 | 41 | 47 | 13 | 23 | 23 |
| Studies conducted by pharmaceutical companies are needed | 11 | 14 | 20 | 72 | 55 | 58 | 18 | 31 | 22 |
| “Academic” studies (not conducted by pharmaceutical companies) are sufficient | 66 | 34 | 27 | 18 | 33 | 47 | 16 | 33 | 27 |
| My NICU uses a standard approach to neonatal care | 5 | 6 | 8 | 79 | 84 | 67 | 16 | 10 | 25 |
| Standard approaches to neonatal care improve neonatal outcomes | 3 | 2 | 10 | 89 | 94 | 63 | 8 | 4 | 27 |
| Research protocols are required to improve a baby’s outcome | 5 | 2 | 0 | 95 | 95 | 90 | 0 | 3 | 10 |
| Research is a central component of my NICU’s work | 3 | 24 | 17 | 76 | 55 | 50 | 21 | 21 | 33 |
| Research should be a central component of a NICU’s work | 8 | 4 | 3 | 82 | 82 | 83 | 8 | 14 | 14 |
| There are sufficient protections for newborn enrolled in a research study | 8.1 | 2.2 | 13 | 81 | 71 | 44.4 | 10.8 | 24.6 | 42.6 |
| Stakeholder Perspectives about Special Protections in Neonatal Research | |||||||||
| Routine adverse event reporting is used to identify safety concerns in neonatal studies | 2.7 | 1.4 | 3.7 | 91.9 | 88.8 | 70.3 | 5.4 | 9.6 | 26 |
| Bedside clinicians who are NOT on the research team contribute to the oversight of NICU studies | 2.7 | 4.44 | 7.4 | 86.4 | 88.2 | 66.7 | 10.8 | 7.3 | 25.9 |
| No special protections are provideda | 78.3 | 77.7 | 55.1 | 10.8 | 3.8 | 8.1 | 10.8 | 18.4 | 36.7 |
| Scientific and ethical review of protocols by neonatal experts provide assurance that benefits of study participation outweigh risksa | 5.4 | 4.6 | 10.2 | 75.6 | 78.4 | 57.1 | 18.9 | 16.9 | 32.6 |
| There are special protections to minimize risk, burden (e.g., limiting the amount of blood drawn) and discomfort of neonates in studiesa | 0 | 3.1 | 4.1 | 86.5 | 76.9 | 67.3 | 13.5 | 20 | 28.5 |
aMD N = 37, RN N = 130, parent N = 49.